These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 34199304)

  • 1. FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice.
    Kommalapati A; Tella SH; Borad M; Javle M; Mahipal A
    Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34199304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality.
    Jain NK; Tailang M; Thangavel N; Makeen HA; Albratty M; Najmi A; Alhazmi HA; Zoghebi K; Alagusundaram M; Jain HK; Chandrasekaran B
    Acta Pharm; 2024 Mar; 74(1):1-36. PubMed ID: 38554385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infigratinib for the Treatment of Metastatic or Locally Advanced Cholangiocarcinoma With Known FGFR2 Gene Fusions or Rearrangements.
    White K; Anwar AI; Jin K; Bollich V; Kelkar RA; Talbot NC; Klapper RJ; Ahmadzadeh S; Viswanath O; Varrassi G; Shekoohi S; Kaye AD
    Cureus; 2023 Oct; 15(10):e46792. PubMed ID: 37954763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibroblast growth factor receptor (FGFR) inhibitors: A review of a novel therapeutic class.
    Weaver A; Bossaer JB
    J Oncol Pharm Pract; 2021 Apr; 27(3):702-710. PubMed ID: 33375902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines.
    Lacouture ME; Sibaud V; Anadkat MJ; Kaffenberger B; Leventhal J; Guindon K; Abou-Alfa G
    Oncologist; 2021 Feb; 26(2):e316-e326. PubMed ID: 33021006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapy.
    Benjamin DJ; Hsu R
    Front Immunol; 2023; 14():1258388. PubMed ID: 37675102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblast growth factor receptors as targets for anticancer therapy in cholangiocarcinomas and urothelial carcinomas.
    Wekking D; Pretta A; Martella S; D'Agata AP; Joeun Choe J; Denaro N; Solinas C; Scartozzi M
    Heliyon; 2023 Sep; 9(9):e19541. PubMed ID: 37681152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.
    Javle M; King G; Spencer K; Borad MJ
    Oncologist; 2023 Nov; 28(11):928-943. PubMed ID: 37390492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
    Aitcheson G; Mahipal A; John BV
    Expert Opin Investig Drugs; 2021 Apr; 30(4):463-477. PubMed ID: 33678096
    [No Abstract]   [Full Text] [Related]  

  • 10. FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions.
    Katoh M; Loriot Y; Brandi G; Tavolari S; Wainberg ZA; Katoh M
    Nat Rev Clin Oncol; 2024 Apr; 21(4):312-329. PubMed ID: 38424198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted Therapy for Advanced or Metastatic Cholangiocarcinoma: Focus on the Clinical Potential of Infigratinib.
    Yu J; Mahipal A; Kim R
    Onco Targets Ther; 2021; 14():5145-5160. PubMed ID: 34720591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pemigatinib: First Approval.
    Hoy SM
    Drugs; 2020 Jun; 80(9):923-929. PubMed ID: 32472305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.
    Subbiah V; Iannotti NO; Gutierrez M; Smith DC; Féliz L; Lihou CF; Tian C; Silverman IM; Ji T; Saleh M
    Ann Oncol; 2022 May; 33(5):522-533. PubMed ID: 35176457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the Fibroblast Growth Factor Receptor (FGFR) in Advanced Cholangiocarcinoma: Clinical Trial Progress and Future Considerations.
    Lee PC; Hendifar A; Osipov A; Cho M; Li D; Gong J
    Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33916849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management.
    Chakrabarti S; Finnes HD; Mahipal A
    Expert Opin Drug Metab Toxicol; 2022 Jan; 18(1):85-98. PubMed ID: 35129006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.
    Roskoski R
    Pharmacol Res; 2020 Jan; 151():104567. PubMed ID: 31770593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pemigatinib in cholangiocarcinoma with a FGFR2 rearrangement or fusion.
    Storandt MH; Jin Z; Mahipal A
    Expert Rev Anticancer Ther; 2022 Dec; 22(12):1265-1274. PubMed ID: 36408971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma.
    Botrus G; Raman P; Oliver T; Bekaii-Saab T
    Expert Opin Investig Drugs; 2021 Apr; 30(4):309-316. PubMed ID: 33307867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma.
    Rizzo A; Ricci AD; Brandi G
    Cancer Treat Res Commun; 2021; 27():100337. PubMed ID: 33611090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors.
    Casadei C; Dizman N; Schepisi G; Cursano MC; Basso U; Santini D; Pal SK; De Giorgi U
    Ther Adv Med Oncol; 2019; 11():1758835919890285. PubMed ID: 31803255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.